Kiniksa Pharmaceuticals International, plc — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised full-year 2026 ARCALYST revenue guidance from $980–995 million to $1.045–1.050 billion, positioning the drug for blockbuster status. As of Q3 end, approximately 23% of 14,000 annual multiple-recurrence pericarditis patients were on ARCALYST; 5,450+ prescribers have written prescriptions. The company reported Q3 net income of $47.3 million (vs. $18.4 million in Q3 2025) and maintains $568.8 million in cash with no debt.
Why this rating
ARCALYST guidance raise of ~$65M mid-point (6.6% of company market cap) signals accelerating commercial traction and blockbuster trajectory; raised earnings materially improve near-term cash generation for $1.1B market-cap company.
Price action (we called it positive)
before filing · preread $76.87 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.